| 1 | A bill to be entitled |
| 2 | An act relating to controlled substances; amending s. |
| 3 | 893.03, F.S.; revising the list of controlled substances |
| 4 | in Schedules I, II, III, IV, and V; providing that the |
| 5 | salts, isomers, or salts of isomers are included within |
| 6 | certain substances listed in Schedule III; providing an |
| 7 | effective date. |
| 8 |
|
| 9 | Be It Enacted by the Legislature of the State of Florida: |
| 10 |
|
| 11 | Section 1. Paragraph (c) of subsection (1), paragraphs (a) |
| 12 | and (b) of subsection (2), paragraph (a) of subsection (3), |
| 13 | subsection (4), and paragraph (b) of subsection (5) of section |
| 14 | 893.03, Florida Statutes, are amended to read: |
| 15 | 893.03 Standards and schedules.-The substances enumerated |
| 16 | in this section are controlled by this chapter. The controlled |
| 17 | substances listed or to be listed in Schedules I, II, III, IV, |
| 18 | and V are included by whatever official, common, usual, |
| 19 | chemical, or trade name designated. The provisions of this |
| 20 | section shall not be construed to include within any of the |
| 21 | schedules contained in this section any excluded drugs listed |
| 22 | within the purview of 21 C.F.R. s. 1308.22, styled "Excluded |
| 23 | Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical |
| 24 | Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted |
| 25 | Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt |
| 26 | Anabolic Steroid Products." |
| 27 | (1) SCHEDULE I.-A substance in Schedule I has a high |
| 28 | potential for abuse and has no currently accepted medical use in |
| 29 | treatment in the United States and in its use under medical |
| 30 | supervision does not meet accepted safety standards. The |
| 31 | following substances are controlled in Schedule I: |
| 32 | (c) Unless specifically excepted or unless listed in |
| 33 | another schedule, any material, compound, mixture, or |
| 34 | preparation which contains any quantity of the following |
| 35 | hallucinogenic substances or which contains any of their salts, |
| 36 | isomers, and salts of isomers, whenever the existence of such |
| 37 | salts, isomers, and salts of isomers is possible within the |
| 38 | specific chemical designation: |
| 39 | 1. Alpha-ethyltryptamine. |
| 40 | 2. 2-Amino-4-methyl-5-phenyl-2-oxazoline (4- |
| 41 | methylaminorex). |
| 42 | 3. 2-Amino-5-phenyl-2-oxazoline (Aminorex). |
| 43 | 4. 4-Bromo-2,5-dimethoxyamphetamine. |
| 44 | 5. 4-Bromo-2, 5-dimethoxyphenethylamine. |
| 45 | 6. Bufotenine. |
| 46 | 7. Cannabis. |
| 47 | 8. Cathinone. |
| 48 | 9. Diethyltryptamine. |
| 49 | 10. 2,5-Dimethoxyamphetamine. |
| 50 | 11. 2,5-Dimethoxy-4-ethylamphetamine (DOET). |
| 51 | 12. Dimethyltryptamine. |
| 52 | 13. N-Ethyl-1-phenylcyclohexylamine (PCE) (Ethylamine |
| 53 | analog of phencyclidine). |
| 54 | 14. N-Ethyl-3-piperidyl benzilate. |
| 55 | 15. N-ethylamphetamine. |
| 56 | 16. Fenethylline. |
| 57 | 17. N-Hydroxy-3,4-methylenedioxyamphetamine. |
| 58 | 18. Ibogaine. |
| 59 | 19. Lysergic acid diethylamide (LSD). |
| 60 | 20. Mescaline. |
| 61 | 21. Methcathinone. |
| 62 | 22. 5-Methoxy-3,4-methylenedioxyamphetamine. |
| 63 | 23. 4-methoxyamphetamine. |
| 64 | 24. 4-methoxymethamphetamine. |
| 65 | 25. 4-Methyl-2,5-dimethoxyamphetamine. |
| 66 | 26. 3,4-Methylenedioxy-N-ethylamphetamine. |
| 67 | 27. 3,4-Methylenedioxyamphetamine. |
| 68 | 28. N-Methyl-3-piperidyl benzilate. |
| 69 | 29. N,N-dimethylamphetamine. |
| 70 | 30. Parahexyl. |
| 71 | 31. Peyote. |
| 72 | 32. N-(1-Phenylcyclohexyl)-pyrrolidine (PCPY) (Pyrrolidine |
| 73 | analog of phencyclidine). |
| 74 | 33. Psilocybin. |
| 75 | 34. Psilocyn. |
| 76 | 35. Salvia divinorum, except for any drug product approved |
| 77 | by the United States Food and Drug Administration which contains |
| 78 | Salvia divinorum or its isomers, esters, ethers, salts, and |
| 79 | salts of isomers, esters, and ethers, whenever the existence of |
| 80 | such isomers, esters, ethers, and salts is possible within the |
| 81 | specific chemical designation. |
| 82 | 36. Salvinorin A, except for any drug product approved by |
| 83 | the United States Food and Drug Administration which contains |
| 84 | Salvinorin A or its isomers, esters, ethers, salts, and salts of |
| 85 | isomers, esters, and ethers, whenever the existence of such |
| 86 | isomers, esters, ethers, and salts is possible within the |
| 87 | specific chemical designation. |
| 88 | 37. Tetrahydrocannabinols. |
| 89 | 38. 1-[1-(2-Thienyl)-cyclohexyl]-piperidine (TCP) |
| 90 | (Thiophene analog of phencyclidine). |
| 91 | 39. 3,4,5-Trimethoxyamphetamine. |
| 92 | 40. Alpha-methyltryptamine. |
| 93 | 41. 1-(1-Phenylcyclohexyl) pyrrolidine. |
| 94 | 42. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine. |
| 95 | 43. 5-Methoxy-N, N-diisopropyltryptamine. |
| 96 | 44. N-Benzylpiperazine. |
| 97 | (2) SCHEDULE II.-A substance in Schedule II has a high |
| 98 | potential for abuse and has a currently accepted but severely |
| 99 | restricted medical use in treatment in the United States, and |
| 100 | abuse of the substance may lead to severe psychological or |
| 101 | physical dependence. The following substances are controlled in |
| 102 | Schedule II: |
| 103 | (a) Unless specifically excepted or unless listed in |
| 104 | another schedule, any of the following substances, whether |
| 105 | produced directly or indirectly by extraction from substances of |
| 106 | vegetable origin or independently by means of chemical |
| 107 | synthesis: |
| 108 | 1. Opium and any salt, compound, derivative, or |
| 109 | preparation of opium, except nalmefene or isoquinoline alkaloids |
| 110 | of opium, including, but not limited to the following: |
| 111 | a. Raw opium. |
| 112 | b. Opium extracts. |
| 113 | c. Opium fluid extracts. |
| 114 | d. Powdered opium. |
| 115 | e. Granulated opium. |
| 116 | f. Tincture of opium. |
| 117 | g. Codeine. |
| 118 | h. Ethylmorphine. |
| 119 | i. Etorphine hydrochloride. |
| 120 | j. Hydrocodone. |
| 121 | k. Hydromorphone. |
| 122 | l. Levo-alphacetylmethadol (also known as levo-alpha- |
| 123 | acetylmethadol, levomethadyl acetate, or LAAM). |
| 124 | m. Metopon (methyldihydromorphinone). |
| 125 | n. Morphine. |
| 126 | o. Oxycodone. |
| 127 | p. Oxymorphone. |
| 128 | q. Thebaine. |
| 129 | r. Dihydroetorphine. |
| 130 | 2. Any salt, compound, derivative, or preparation of a |
| 131 | substance which is chemically equivalent to or identical with |
| 132 | any of the substances referred to in subparagraph 1., except |
| 133 | that these substances shall not include the isoquinoline |
| 134 | alkaloids of opium. |
| 135 | 3. Any part of the plant of the species Papaver |
| 136 | somniferum, L. |
| 137 | 4. Cocaine or ecgonine, including any of their |
| 138 | stereoisomers, and any salt, compound, derivative, or |
| 139 | preparation of cocaine or ecgonine. |
| 140 | (b) Unless specifically excepted or unless listed in |
| 141 | another schedule, any of the following substances, including |
| 142 | their isomers, esters, ethers, salts, and salts of isomers, |
| 143 | esters, and ethers, whenever the existence of such isomers, |
| 144 | esters, ethers, and salts is possible within the specific |
| 145 | chemical designation: |
| 146 | 1. Alfentanil. |
| 147 | 2. Alphaprodine. |
| 148 | 3. Anileridine. |
| 149 | 4. Bezitramide. |
| 150 | 5. Bulk propoxyphene (nondosage forms). |
| 151 | 6. Carfentanil. |
| 152 | 7. Dihydrocodeine. |
| 153 | 8. Diphenoxylate. |
| 154 | 9. Fentanyl. |
| 155 | 10. Isomethadone. |
| 156 | 11. Levomethorphan. |
| 157 | 12. Levorphanol. |
| 158 | 13. Metazocine. |
| 159 | 14. Methadone. |
| 160 | 15. Methadone-Intermediate,4-cyano-2- |
| 161 | dimethylamino-4,4-diphenylbutane. |
| 162 | 16. Moramide-Intermediate,2-methyl- |
| 163 | 3-morpholoino-1,1-diphenylpropane-carboxylic acid. |
| 164 | 17. Nabilone. |
| 165 | 18. Pethidine (meperidine). |
| 166 | 19. Pethidine-Intermediate-A,4-cyano-1- |
| 167 | methyl-4-phenylpiperidine. |
| 168 | 20. Pethidine-Intermediate-B,ethyl-4- |
| 169 | phenylpiperidine-4-carboxylate. |
| 170 | 21. Pethidine-Intermediate-C,1-methyl-4- phenylpiperidine- |
| 171 | 4-carboxylic acid. |
| 172 | 22. Phenazocine. |
| 173 | 23. Phencyclidine. |
| 174 | 24. 1-Phenylcyclohexylamine. |
| 175 | 25. Piminodine. |
| 176 | 26. 1-Piperidinocyclohexanecarbonitrile. |
| 177 | 27. Racemethorphan. |
| 178 | 28. Racemorphan. |
| 179 | 29. Sufentanil. |
| 180 | 30. Lisdexamfetamine. |
| 181 | 31. Remifentanil. |
| 182 | (3) SCHEDULE III.-A substance in Schedule III has a |
| 183 | potential for abuse less than the substances contained in |
| 184 | Schedules I and II and has a currently accepted medical use in |
| 185 | treatment in the United States, and abuse of the substance may |
| 186 | lead to moderate or low physical dependence or high |
| 187 | psychological dependence or, in the case of anabolic steroids, |
| 188 | may lead to physical damage. The following substances are |
| 189 | controlled in Schedule III: |
| 190 | (a) Unless specifically excepted or unless listed in |
| 191 | another schedule, any material, compound, mixture, or |
| 192 | preparation which contains any quantity of the following |
| 193 | substances having a depressant or stimulant effect on the |
| 194 | nervous system, including its salts, isomers, and salts of |
| 195 | isomers whenever the existence of such salts, isomers, or salts |
| 196 | of isomers is possible within the specific chemical designation: |
| 197 | 1. Any substance which contains any quantity of a |
| 198 | derivative of barbituric acid, including thiobarbituric acid, or |
| 199 | any salt of a derivative of barbituric acid or thiobarbituric |
| 200 | acid, including, but not limited to, butabarbital and |
| 201 | butalbital. |
| 202 | 2. Benzphetamine. |
| 203 | 3. Chlorhexadol. |
| 204 | 4. Chlorphentermine. |
| 205 | 5. Clortermine. |
| 206 | 6. Lysergic acid. |
| 207 | 7. Lysergic acid amide. |
| 208 | 8. Methyprylon. |
| 209 | 9. Phendimetrazine. |
| 210 | 10. Sulfondiethylmethane. |
| 211 | 11. Sulfonethylmethane. |
| 212 | 12. Sulfonmethane. |
| 213 | 13. Tiletamine and zolazepam or any salt thereof. |
| 214 | 14. Embutramide. |
| 215 | (4) SCHEDULE IV.-A substance in Schedule IV has a low |
| 216 | potential for abuse relative to the substances in Schedule III |
| 217 | and has a currently accepted medical use in treatment in the |
| 218 | United States, and abuse of the substance may lead to limited |
| 219 | physical or psychological dependence relative to the substances |
| 220 | in Schedule III. Unless specifically excepted or unless listed |
| 221 | in another schedule, any material, compound, mixture, or |
| 222 | preparation which contains any quantity of the following |
| 223 | substances, including its salts, isomers, and salts of isomers |
| 224 | whenever the existence of such salts, isomers, and salts of |
| 225 | isomers is possible within the specific chemical designation, |
| 226 | are controlled in Schedule IV: |
| 227 | (a) Alprazolam. |
| 228 | (b) Barbital. |
| 229 | (c) Bromazepam. |
| 230 | (d) Camazepam. |
| 231 | (e) Cathine. |
| 232 | (f) Chloral betaine. |
| 233 | (g) Chloral hydrate. |
| 234 | (h) Chlordiazepoxide. |
| 235 | (i) Clobazam. |
| 236 | (j) Clonazepam. |
| 237 | (k) Clorazepate. |
| 238 | (l) Clotiazepam. |
| 239 | (m) Cloxazolam. |
| 240 | (n) Delorazepam. |
| 241 | (o) Propoxyphene (dosage forms). |
| 242 | (p) Diazepam. |
| 243 | (q) Diethylpropion. |
| 244 | (r) Estazolam. |
| 245 | (s) Ethchlorvynol. |
| 246 | (t) Ethinamate. |
| 247 | (u) Ethyl loflazepate. |
| 248 | (v) Fencamfamin. |
| 249 | (w) Fenfluramine. |
| 250 | (x) Fenproporex. |
| 251 | (y) Fludiazepam. |
| 252 | (z) Flurazepam. |
| 253 | (aa) Halazepam. |
| 254 | (bb) Haloxazolam. |
| 255 | (cc) Ketazolam. |
| 256 | (dd) Loprazolam. |
| 257 | (ee) Lorazepam. |
| 258 | (ff) Lormetazepam. |
| 259 | (gg) Mazindol. |
| 260 | (hh) Mebutamate. |
| 261 | (ii) Medazepam. |
| 262 | (jj) Mefenorex. |
| 263 | (kk) Meprobamate. |
| 264 | (ll) Methohexital. |
| 265 | (mm) Methylphenobarbital. |
| 266 | (nn) Midazolam. |
| 267 | (oo) Nimetazepam. |
| 268 | (pp) Nitrazepam. |
| 269 | (qq) Nordiazepam. |
| 270 | (rr) Oxazepam. |
| 271 | (ss) Oxazolam. |
| 272 | (tt) Paraldehyde. |
| 273 | (uu) Pemoline. |
| 274 | (vv) Pentazocine. |
| 275 | (ww) Phenobarbital. |
| 276 | (xx) Phentermine. |
| 277 | (yy) Pinazepam. |
| 278 | (zz) Pipradrol. |
| 279 | (aaa) Prazepam. |
| 280 | (bbb) Propylhexedrine, excluding any patent or proprietary |
| 281 | preparation containing propylhexedrine, unless otherwise |
| 282 | provided by federal law. |
| 283 | (ccc) Quazepam. |
| 284 | (ddd) Tetrazepam. |
| 285 | (eee) SPA[(-)-1 dimethylamino-1, 2 diphenylethane]. |
| 286 | (fff) Temazepam. |
| 287 | (ggg) Triazolam. |
| 288 | (hhh) Not more than 1 milligram of difenoxin and not less |
| 289 | than 25 micrograms of atropine sulfate per dosage unit. |
| 290 | (iii) Butorphanol tartrate. |
| 291 | (jjj) Carisoprodol. |
| 292 | (kkk) Zopiclone. |
| 293 | (lll) Zaleplon. |
| 294 | (mmm) Zolpidem. |
| 295 | (nnn) Modafinil. |
| 296 | (ooo) Petrichloral. |
| 297 | (ppp) Sibutramine. |
| 298 | (qqq) Dichloralphenazone. |
| 299 | (5) SCHEDULE V.-A substance, compound, mixture, or |
| 300 | preparation of a substance in Schedule V has a low potential for |
| 301 | abuse relative to the substances in Schedule IV and has a |
| 302 | currently accepted medical use in treatment in the United |
| 303 | States, and abuse of such compound, mixture, or preparation may |
| 304 | lead to limited physical or psychological dependence relative to |
| 305 | the substances in Schedule IV. |
| 306 | (b) Narcotic drugs. Unless specifically excepted or unless |
| 307 | listed in another schedule, any material, compound, mixture, or |
| 308 | preparation containing any of the following narcotic drugs and |
| 309 | their salts: |
| 310 | 1. Buprenorphine. |
| 311 | 2. Pregabalin. |
| 312 | 3. Not more than 0.5 milligrams of difenoxin and not less |
| 313 | than 25 micrograms of atrophine sulfate per dosage unit. |
| 314 | Section 2. This act shall take effect July 1, 2010. |